Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CX-072 + Ipilimumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CX-072 | CX072|CX 072|Pacmilimab | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | CX-072 (Pacmilimab) is a prodrug consisting of a monoclonal antibody to PD-L1 (CD274) and a masking peptide that is cleaved by proteases specific to tumor cells (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3072-3072, PMID: 32681519). | |
Ipilimumab | Yervoy | BMS-734016 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 | Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03013491 | Phase II | CX-072 + Ipilimumab CX-072 + Vemurafenib CX-072 | A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | Completed | USA | POL | NLD | GBR | ESP | 1 |